ScholarLens Back to search
2021•Global Journal of Cancer TherapyOpen access

Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma

Amany R. Keruakous, Day Silas, Yuen Carrie

Open full text 0 citations

Abstract

Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to its favorable impact on overall survival.

Open-access reader

About this research paper

What this paper is about

Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to its favorable impact on overall survival.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to its favorable impact on overall survival.

Key concepts: Lenalidomide, Bortezomib, Multiple myeloma, Regimen, Dexamethasone, Oncology, Internal medicine, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma — Research Paper | ScholarLens